Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
April 30, 2024 05:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
April 01, 2024 08:00 ET
|
Cingulate Inc.
$17.8 Million Raised Since Beginning of 2023$9.1 Million of Debt Converted to Equity at a PremiumPhase 3 ADHD Data Continues to Impress KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE) --...
C.K. McWhorter Honoring Excellence Of Rolex: McWhorter Family Trust Recognizes Rolex as a Paragon of Timepiece Craftsmanship By Granting Illustrious Trust Warrant
March 16, 2024 13:16 ET
|
McWhorter Foundation
C.K. McWhorter Honoring Excellence Of Rolex: McWhorter Family Trust Recognizes Rolex as a Paragon of Timepiece Craftsmanship
Cingulate to Attend DCAT Week 2024 in New York City
March 06, 2024 06:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
February 13, 2024 06:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Announces Closing of $7.5 Million Public Offering
February 06, 2024 16:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate Announces Pricing of $7.5 Million Public Offering
February 02, 2024 09:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Superblock to Provide Monthly Blockchain Reports on Bloomberg Terminal
January 29, 2024 09:00 ET
|
Superblock
SEOUL, South Korea, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Superblock, the main contributor of the ‘Over Protocol’ mainnet, provides a blockchain insight report to Bloomberg Terminal. Superblock...
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
January 29, 2024 06:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Nano Dimension Announces Preliminary All Cash Proposal to Acquire Stratasys for $16.50 per share
December 23, 2023 09:00 ET
|
Nano Dimension Ltd.
Waltham, Mass., Dec. 23, 2023 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension”, or “Nano” or the “Company”), a leading supplier of Additively Manufactured Electronics...